"Lilly's drug works similarly to semaglutide, which is sold by Novo Nordisk under the brand names Ozempic and Wegovy. It mimics a gut hormone responsible which binds to the GLP-1 receptor for regulating blood sugar levels and your perception of hunger, in effect suppressing your appetite. But retatrutide is no mere GLP-1 agonist, as semaglutide and others like it are known. It's being hailed as a first-of-its-kind "Tripl e G" drug because it targets the GLP-1 receptor, the GIP receptor, and the GCG receptor."
"Though it's yet to hit the mainstream, it's been a hit with so-called "grey market pharmacies" that sell unapproved drugs under the guise that they' re only for "research purposes." Such pharmacies can be a vital pipeline of hormones and other compounds for trans and non-binary people seeking gender-affirming care, providing affordable alternatives to what you'd get through your health insurance, but they're also an outlet of drugs with questions about their efficacy and safety, like anabolic steroids and human growth hormone."
Retatrutide is an investigational weight-loss drug developed by Eli Lilly that remains in clinical trials and is not yet approved. The molecule acts on gut-hormone pathways, mimicking hormones that bind the GLP-1 receptor to reduce hunger and regulate blood sugar. Retatrutide combines activity at GLP-1, GIP, and GCG receptors as a single "Triple G" tri-agonist. A phase II trial reported an average 24.2 percent body-weight reduction over 48 weeks in obese participants. Unapproved supplies have entered grey-market pharmacies marketed for "research purposes," creating access and safety concerns alongside use for gender-affirming care.
Read at Futurism
Unable to calculate read time
Collection
[
|
...
]